Breaking New Ground: Psychedelics in Modern Psychiatry, Part 1

Psychedelic Therapy for Mental Health: Research, Safety, and the Path to FDA Approval: Dr. Will Van Derveer and Keith Kurlander, co-authors of “Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life,” reveal the shift from recreational psychedelics to structured, research-based psychedelic-assisted therapy for conditions like PTSD, depression, and anxiety. Van Derveer describes limitations of conventional psychiatry (citing STAR*D remission rates) and his entry into MDMA-assisted PTSD research after promising results. They contrast controlled clinical protocols—screening, preparation, safe setting, trained facilitation, medical monitoring, and post-session integration—with uncontained recreational use. The discussion covers current policy momentum under Trump and RFK Jr., VA interest for veterans, and key agents: ketamine (including abuse risks and clinic-only Spravato), MDMA (phase 3 but not approved in 2024), psilocybin (phase 3, potential FDA approval), LSD (GAD trials), ibogaine (arrhythmia risk, Mexico clinics), ayahuasca, peyote, and microdosing. They also note commercialization, including Eli Lilly’s acquisition of a 5-MeO-DMT nasal spray developer, and emphasize an integrative “all-of-the-above” mental health approach.